At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 149 enrolled
Drug / intervention
Ferric Citrate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
In Brief
A Phase 2 clinical trial evaluating Ferric Citrate and Placebo for Iron Deficiency and Iron Deficiency Anemia. Completed, enrolled 149 participants across 20 sites.
Detailed Summary
The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of treatment is approximately 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency, Iron Deficiency Anemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionNov 2013
Study CompletionDec 2013
TodayJul 2026
First PostedNov 29, 2012
Enrollment StartNov 1, 2012
Primary CompletionNov 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.6 years ago
Interventions
Ferric Citratedrug
Dose depends on serum phosphorus levels collected at each study visit.
Placebodrug